NCT06262594 (L'ÉTOILE) is a Phase 3 clinical trial of Lemborexant in Epilepsy, sponsored by University of Manitoba.

Who is sponsoring NCT06262594?

NCT06262594 is sponsored by University of Manitoba.

What drugs are being tested in NCT06262594?

Interventions in NCT06262594: Lemborexant, Placebo.

What condition does NCT06262594 study?

NCT06262594 studies Epilepsy, Sleep.

Is NCT06262594 still recruiting?

NCT06262594 is currently recruiting now. Last updated 13 February 2025.

Last reviewed 2025-02-13 · How we verify

NCT06262594: L'ÉTOILE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lemborexant Treatment of Insomnia Linked to Epilepsy

Recruiting now Phase 3 Last updated 13 February 2025

What this trial tests

Phase 3 trial testing Lemborexant in Epilepsy in 26 participants. Currently enrolling.

Timeline

29 October 2024

Primary endpoint
18 April 2026

18 April 2027

Quick facts

Lead sponsor	University of Manitoba
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	26
Start date	29 October 2024
Primary completion	18 April 2026
Estimated completion	18 April 2027
Sites	2 locations across Canada, United States

Drugs / interventions tested

Lemborexant (LEMBOREXANT) — full drug profile →
Placebo

Conditions studied

Epilepsy — all drugs for Epilepsy →
Sleep — all drugs for Sleep →

Sponsor

University of Manitoba

Who can join

18 and older, any sex, with Epilepsy or Sleep. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lemborexant

Trials testing the same drug.

NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07480096 — Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems · Phase 2 · completed
NCT06874855 — Lemborexant in Delayed Sleep Phase Syndrome · Phase 4 · recruiting
NCT05594589 — A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder · Phase 2 · completed

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06262594 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 13 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06262594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing